Dexcom Inc (NASDAQ: DXCM)’s stock price has dropped by -9.91 in relation to previous closing price of 138.01. Nevertheless, the company has seen a loss of -4.87% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-26 that DexCom’s (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Is It Worth Investing in Dexcom Inc (NASDAQ: DXCM) Right Now?
Dexcom Inc (NASDAQ: DXCM) has a higher price-to-earnings ratio of 80.27x compared to its average ratio. DXCM has 36-month beta value of 1.20. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 8 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for DXCM is 387.71M, and currently, short sellers hold a 3.04% ratio of that float. The average trading volume of DXCM on April 29, 2024 was 3.10M shares.
DXCM’s Market Performance
DXCM’s stock has seen a -4.87% decrease for the week, with a -10.85% drop in the past month and a 1.95% gain in the past quarter. The volatility ratio for the week is 5.07%, and the volatility levels for the past 30 days are at 3.43% for Dexcom Inc. The simple moving average for the past 20 days is -8.97% for DXCM’s stock, with a 7.99% simple moving average for the past 200 days.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with RBC Capital Mkts repeating the rating for DXCM by listing it as a “Outperform.” The predicted price for DXCM in the upcoming period, according to RBC Capital Mkts is $165 based on the research report published on March 12, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $131. The rating they have provided for DXCM stocks is “Equal-Weight” according to the report published on May 30th, 2023.
Raymond James gave a rating of “Strong Buy” to DXCM, setting the target price at $138 in the report published on April 17th of the previous year.
DXCM Trading at -4.76% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.44% of loss for the given period.
Volatility was left at 3.43%, however, over the last 30 days, the volatility rate increased by 5.07%, as shares sank -10.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.50% upper at present.
During the last 5 trading sessions, DXCM fell by -4.87%, which changed the moving average for the period of 200-days by -6.98% in comparison to the 20-day moving average, which settled at $135.88. In addition, Dexcom Inc saw 0.20% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from Dolan Matthew Vincent, who sale 1,990 shares at the price of $137.81 back on Apr 15 ’24. After this action, Dolan Matthew Vincent now owns 42,377 shares of Dexcom Inc, valued at $274,242 using the latest closing price.
SAYER KEVIN R, the President CEO and Chairman of Dexcom Inc, sale 49,633 shares at $138.30 during a trade that took place back on Apr 08 ’24, which means that SAYER KEVIN R is holding 283,893 shares at $6,864,136 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.63 for the gross margin
The net margin for Dexcom Inc stands at 0.17. The total capital return value is set at 0.13. Equity return is now at value 28.54, with 10.66 for asset returns.
Based on Dexcom Inc (DXCM), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at 0.31. The debt to equity ratio resting at 1.15. The interest coverage ratio of the stock is 32.1.
Currently, EBITDA for the company is 916.7 million with net debt to EBITDA at 2.0. When we switch over and look at the enterprise to sales, we see a ratio of 13.41. The receivables turnover for the company is 3.86for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.90.
Conclusion
To put it simply, Dexcom Inc (DXCM) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
